Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial

Urol Int. 1991;47(3):138-43. doi: 10.1159/000282207.

Abstract

In a multicentre placebo-controlled double-blind study 61 patients with spinal cord injuries and detrusor hyperreflexia were treated: 20 mg trospium chloride was given twice daily over a period of 3 weeks. Pre- and posttreatment urodynamic measurements demonstrated large improvements in maximum cystometric capacity (mean = 138.1 ml), decreased maximum detrusor pressure (mean = -37.8 cm H2O) and an increase in compliance (mean = 12.1 ml/cm H2O) in the treatment group. Urodynamic parameters in the placebo group remained substantially unchanged. Comparisons between the two groups revealed highly significant differences for these parameters (all, p less than 0.001). No effect on maximum flow rate and residual urine was detected in either group. The incidence of spontaneously reported side-effects was extremely low and comparable for both groups.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Benzilates
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Nortropanes / adverse effects
  • Nortropanes / therapeutic use*
  • Parasympatholytics / adverse effects
  • Parasympatholytics / therapeutic use*
  • Pressure
  • Spinal Cord Injuries / complications*
  • Urinary Bladder / physiopathology
  • Urinary Bladder, Neurogenic / drug therapy*
  • Urinary Bladder, Neurogenic / etiology
  • Urinary Bladder, Neurogenic / physiopathology
  • Urodynamics

Substances

  • Benzilates
  • Nortropanes
  • Parasympatholytics
  • trospium chloride